Propiverine is an anticholinergic drug used for the treatment of urinary urgency, frequency and urge incontinence, all symptoms of overactive bladder syndrome. It is a muscarinic antagonist. Technically, propiverine hydrochloride acts primarily by blocking muscarinic M2 and M3 receptors in the detrusor smooth muscle, reducing involuntary bladder contractions and increasing bladder capacity. It is available as the hydrochloride salt for oral administration, is well absorbed with peak plasma concentrations typically within 1 to 3 hours after an immediate release dose, and undergoes hepatic metabolism to several active and inactive metabolites. Clinical pharmacology data indicate a plasma elimination half life in the range of several hours with metabolites that may persist longer, and dose selection is guided by efficacy and tolerability considerations in each patient.
Parent: Propiverine
Parent: Propiverine
Parent: Propiverine Hydrochloride / Propiverine
Parent: Propiverine
Parent: Propiverine
Parent: Propiverine
Manufacturing and quality control of propiverine hydrochloride monitor defined related substances and unspecified impurities to ensure safety and stability; typical analytical acceptance criteria seen in commercial specifications are that individual related impurities do not exceed about 0.10 percent w/w and total related compounds do not exceed about 0.50 percent w/w, with unspecified impurities reported down to 0.05 percent w/w or lower according to regulatory reporting thresholds. Common related compounds and degradants encountered during synthesis and stability studies include N-dealkylated and N-oxide derivatives, hydroxylated metabolites, desmethyl species, residual synthetic intermediates and trace levels of starting material, plus residual solvents which are controlled to pharmacopeial and ICH Q3C limits. Specifications also include tests for assay, heavy metals, water content and microbial limits as appropriate for an active pharmaceutical ingredient.
Clinical trials and practice show both oxybutynin and propiverine are effective antimuscarinic treatments for overactive bladder; which is better depends on individual response and tolerability. Oxybutynin may be associated with more central nervous system and dry mouth effects in some patients, while propiverine may have a different side effect profile and metabolic pattern. Choice should be guided by efficacy for the individual, adverse event profile, comorbidities and clinician judgement.
The elimination half life of propiverine after an immediate release oral dose is generally reported in the range of approximately 8 to 12 hours, although values can vary with formulation and individual metabolism; some metabolites may have longer persistence.
The generic name for Mictoryl is propiverine, commonly supplied as propiverine hydrochloride in marketed formulations.
Propiverine hydrochloride 30 mg refers to an oral dosage strength formulation that contains 30 milligrams of propiverine expressed as the hydrochloride salt; it is a prescription strength used for management of overactive bladder and dosing regimens should follow approved product labeling and clinician instructions.
